Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed, along with the need for diversification. Cramer highlighted that he is fond of the stock, as he said: “You could own JNJ and Merck with their incredible franchises. You know what? I’m actually particularly fond of JNJ right now. They’re spinning off their commoditized artificial joint business.” Photo by Adam Nowakowski on Unsplash Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and m ...

I have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeking Alpha community.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ABBV, ADP, CTAS, FDS, HRL, JNJ, LOW, NEE, O, PEP, TROW, WST either through stock ownership, opti ...

The Dow Jones Industrial Average (^DJI) closed higher on Friday, November 28, 2025, gaining 289.30 (0.61%) points in a shortened Black Friday trading session. Dow Futures (YM=F) also reflected positive sentiment, rising 253.00 (0.5327%). The primary narrative driving the market today was strong optimism surrounding the Black Friday shopping period and the broader holiday retail season, signaling robust consumer spending expectations. This positive outlook propelled a broad range of sectors, particularly tho ...

The Dow Jones Industrial Average (^DJI) was up 289.30 (0.61%) today, with Dow Futures (YM=F) also showing strength, up 253.00 (0.5327%). The positive market momentum in this shortened Black Friday trading session was largely driven by optimism surrounding potential Federal Reserve interest rate cuts in the near future, coupled with generally strong economic data. This sentiment propelled a broad-based rally across the major indices.Several key components and significant stocks posted notable gains. JPMorgan ...

Try our mini crossword with a business twist: Play Fast Company Mini Crossword LOGIN SUBSCRIBE | Custom Studio advertisement In the latest sign that the Trump administration isn't so concerned about asbestos, the Food and Drug Administration this week withdrew a proposed rule that would have required testing for the toxic asbestos in talc-based cosmetics. The rule, which was proposed by the Biden administration less than a year ago, would have required manufacturers to test cosmetics for asbestos and keep r ...

The Dow Jones Industrial Average (^DJI) saw positive movement today, Friday, November 28, 2025, rising 315.72 points or 0.6657% to 47742.84. This upward trend occurred during a shortened Black Friday trading session, with markets closing early at 1 p.m. ET. The broader market narrative was largely driven by renewed optimism for a potential Federal Reserve interest rate cut in December, alongside generally stronger-than-expected economic data. This sentiment helped propel equities despite an overnight techni ...

Women We Admire is pleased to announce The Top 25 Women Editors in Chief for 2025NEW YORK, Nov. 28, 2025 /PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Top 25 Women Editors in Chief for 2025. Editors in chief play one of the most pivotal roles in modern media. As the ultimate decision-makers for what appears on the page or on screen, they guide the editorial vision, shape content strategy, and uphold the standards of accuracy, fairness, and creativity that define trusted journalism. These ...

Key Takeaways JNJ's oncology sales rose 20.6% to $18.52B on strong growth of key cancer drugs.JNJ targets $50B in oncology sales by decade-end.A $3.05B deal for Halda Therapeutics adds targeted cancer medicines to JNJ's portfolio.Johnson & Johnson (JNJ) is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors.Its Oncology segment, at present, comprises around 27% of its total revenues. Its oncology sales rose 20.6% on an operational basis ...

Group 1: Market Sentiment and Trends - CNBC host Jim Cramer has become more cautious toward AI and data center stocks due to increasing insider selling and borrowing activity, indicating a shift from the previous era of "magical investing" [1] - Cramer has revised his outlook on data center companies, stating that the favorable investment period is over and has declared it "dead" [1] Group 2: Stock Recommendations - Cramer recommends holding shares of TJX Companies (NYSE:TJX), emphasizing its strength in a downturn, with the stock up 21% this year and a dividend yield of about 1.2% [3] - Energy Transfer LP Unit (NYSE:ET) is highlighted as a high-yield dividend stock, despite being down 13% this year and missing Q3 estimates, with a dividend yield of approximately 7.8% [4] - Procter & Gamble (NYSE:PG) is viewed as an attractive investment opportunity in a down market, offering a dividend yield of 2.85% and demonstrating strong operational efficiency [5][6] - Johnson & Johnson (NYSE:JNJ) received a bullish outlook following FDA approval of its Caplyta drug for treating major depressive disorder [6][8]

Johnson & Johnson (JNJ) is a global healthcare conglomerate, renowned for its broad presence in pharmaceuticals and medical devices. Headquartered in New Brunswick, New Jersey, its market cap is around $500.1 billion. Johnson & Johnson has evolved into one of the world’s largest and most diversified healthcare firms, with a global workforce and a portfolio spanning cutting-edge therapeutics, medical technologies, and historically, consumer health brands. Companies worth $200 billion or more are generally ...